MCAD Inhibitors

MCAD inhibitors are a diverse group of chemicals that modulate the activity of Medium-Chain Acyl-CoA Dehydrogenase, an enzyme critical in the mitochondrial β-oxidation pathway of medium-chain fatty acids. These inhibitors can be direct or indirect, depending on their mode of action. Direct inhibitors like Etomoxir and Perhexiline interact with the active site of the enzyme, impeding the catalytic dehydrogenation of medium-chain acyl-CoAs. This specific interaction is crucial for the targeting of MCAD in various metabolic disorders.

Indirect inhibitors, on the other hand, influence MCAD activity by modifying related metabolic pathways or by causing the accumulation of metabolites that interfere with the enzyme's function. Compounds such as Hypoglycin A, Meldonium, and Fenofibrate fall into this category. They modulate the enzyme's activity not by direct interaction but through broader metabolic effects. For example, Hypoglycin A leads to the accumulation of metabolites that hinder MCAD's function, while Meldonium and Fenofibrate adjust cellular energy metabolism, consequently impacting fatty acid oxidation. This indirect inhibition is significant because it provides alternative strategies for conditions where direct inhibition of MCAD is not feasible or where a broader modulation of metabolic pathways is beneficial.